New hemophilia drug aims to outperform current standard in bleeding prevention

NCT ID NCT07416604

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Feb 21, 2026 · Last updated May 13, 2026 · Updated 11 times

Summary

This study tests a new medicine called NXT007 against an existing drug, emicizumab, to see which better prevents bleeding episodes in people with hemophilia A. The trial includes 360 participants aged 12 and older with severe or moderate hemophilia A, with or without inhibitors. The main goal is to measure how many bleeding events require treatment over the study period.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Center for Inherited Blood Disorders
RECRUITING

Orange, California, 92868, United States
Gunma University Hospital
RECRUITING

Maebashi, Gunma, 371-8511, Japan
Innovative Hematology, Inc.
RECRUITING

Indianapolis, Indiana, 46260, United States
Nara Medical University Hospital
RECRUITING

Kashihara-shi, Nara, 634-8522, Japan
Ogikubo Hospital
RECRUITING

Suginami-Ku, Tokyo, 167-0035, Japan
Washington Center for Bleeding Disorders
RECRUITING

Seattle, Washington, 98101-3932, United States

Conditions

Explore the condition pages connected to this study.

HEMOPHILIA A